The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Editorial

The Rise and Fall of Vancomycin

Authors: Rose A. Recco, MD

Abstract

Since its development in the 1950s, vancomycin has had a prominent role in the treatment of staphylococcal infections. Soon after its debut, the first cases of methicillin-resistant Staphylococcus aureus (MRSA) were reported (1961),1 but remained a rarity until the late 1970s.2

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536–1542.
 
2. Recco RA, Schaffler S, Gladstone JL. A hospital outbreak of methicillin-resistant Staphylococcus aureus. Abstract Presented at: American Federation for Clinical Research (Eastern Section), January 14, 1977.
 
3. Herold BC, Immegluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593–598.
 
4. Grundmann H, Aires-de-Sousa J, Boyce J, et al. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006;368:877–885.
 
5. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin. MMWR Morb Mortal Wkly Rep 1997;46:624–626.
 
6. Levine DP. Vancomycin: understanding its past and preserving its future. South Med J 2008;101:284–291.
 
7. Deresinsk S. Counterpoint: vancomycin and Staphylococcus aureus—an antibiotic enters obsolescence. Clin Infect Dis 2007;44:1543–1548.
 
8. Daum RS. Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007:357:380–390.
 
9. Wunderink RG, Rello J, Cammarta SK, et al. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789–1797.